Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Kenya president postpones reopening of schools as floodFloyd Mayweather gifts $30k to homeless men before ClippersKylie Minogue reveals her unlikely friendship with Coldplay's Chris MartinThree groups are suing New Jersey to block an offshore wind farmI spent £2,000 on surgery to remove my double chinJill Biden recognizes fellow teachers at White House dinnerJay Blades' wife Lisa shares cryptic message in the wake of couple's splitJessie Buckley is seen flying up a building as Christian Bale gets his Frankenstein makeJessie Buckley is seen flying up a building as Christian Bale gets his Frankenstein makeJill Biden recognizes fellow teachers at White House dinner
3.3715s , 6497.5703125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Stellar Standpoint news portal